UNASSIGNED: @entity9576 ( @entity9576 ) is a rapidly-progressive @entity179 characterized by @entity304 , @entity6447 and @entity11460 . A pathological hallmark of @entity9576 is the presence of a-synuclein deposits in oligodendrocytes, the myelin-producing support cells of the brain. Brain pathology and in vitro studies indicate that myelin instability may be an early event in the pathogenesis of @entity9576 . Lipid is a major constituent (78% w/w) of myelin and has been implicated in @entity17 in @entity9576 . However, changes, if any, in lipid level/distribution in @entity9576 brain are unknown. Here, we undertook a comprehensive analysis of @entity9576 myelin. We quantitatively measured three groups of lipids, sphingomyelin, @entity10839 and @entity15226 , which are all important in myelin integrity and function, in affected (under the motor cortex) and unaffected (under the visual cortex) white matter regions. For all three groups of lipids, most of the species were severely decreased (40-69%) in affected but not unaffected @entity9576 white matter. An analysis of the distribution of lipid species showed no significant shift in @entity844 chain length/content with @entity9576 . The decrease in lipid levels was concomitant with increased a-synuclein expression. These data indicate that the absolute levels, and not distribution, of myelin lipids are altered in @entity9576 , and provide evidence for myelin lipid dysfunction in @entity9576 pathology. We propose that @entity17 in the course of @entity9576 pathogenesis may trigger myelin instability.

Altered lipid levels provide evidence for XXXX in multiple system atrophy.

@entity17 :: ('MESH:D003711', 'Disease') :: ['myelin dysfunction', 'dysregulation of myelin lipids'] @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid'] @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism'] @entity9576 :: ('MESH:D019578', 'Disease') :: ['MSA', 'Multiple system atrophy'] @entity15226 :: ('CHEBI:36498', 'Chemical') :: ['galactosylceramide'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disease'] @entity6447 :: ('MESH:D002524', 'Disease') :: ['cerebellar ataxia'] @entity10839 :: ('CHEBI:18318', 'Chemical') :: ['sulfatide'] @entity11460 :: ('MESH:D012791', 'Disease') :: ['autonomic failure']
@entity17 :: (MESH:D003711,Disease) :: ['myelin dysfunction']
